Investigational drug · Phase 2
NBM-BMX
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Malignant Neoplasm of Brain, Malignant Neoplasm.
Phase 2Last checked: Nov 19, 2026Latest source record: May 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
5
Any phase or sponsor naming "NBM-BMX"
First trial start
2023
Aug 11, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NBM-BMX", any sponsor or status.
Conditions studied
As listed on its trial records.
- Malignant Neoplasm of Brain
- Malignant Neoplasm
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "NBM-BMX" as an intervention, largest first.
Novelwise Pharmaceutical CorporationIndustry
NCT06012695 · 79 participants (planned) · Start Aug 11, 2023 · Primary completion May 30, 2028
Drug: NBM-BMX Capsule; Temozolomide · For: Malignant Neoplasm; Malignant Neoplasm of Brain
Sites: Kaohsiung City, Taiwan; Taichung, Taiwan; Taipei, Taiwan · 4 sites in all
Novelwise Pharmaceutical CorporationIndustry
NCT07136181 · 36 participants (planned) · Start Nov 20, 2025 · Primary completion Mar 28, 2028
Drug: NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of patients suffering from cancers. · For: Metastatic Uveal Melanoma; Uveal Melanoma, Metastatic; Uveal Melanoma, Recurrent and 2 more
Sites: Scottsdale, Arizona; Denver, Colorado; Nashville, Tennessee
- A Safety and Pharmacokinetic Study of NBM-BMX Administered Orally to Patients With Advanced CancerCompleted
NatureWise Biotech & Medicals CorporationIndustry
NCT03726294 · 33 participants · Start Oct 16, 2018 · Primary completion Apr 24, 2020
Drug: NBM-BMX softgel capsules · For: Malignant Neoplasm
Sites: San Antonio, Texas
NatureWise Biotech & Medicals CorporationIndustry
NCT03808870 · 21 participants · Start Dec 28, 2018 · Primary completion Feb 12, 2022
Drug: NBM-BMX softgel capsules · For: Malignant Neoplasm
Sites: Tainan, Taiwan; Taipei, Taiwan
Novelwise Pharmaceutical CorporationIndustry
NCT07569042 · 15 participants (planned) · Start Apr 20, 2026 · Primary completion Sep 30, 2029
Drug: NBM-BMX Capsule; Temozolomide · For: Malignant Neoplasm of Brain
Sites: Kaohsiung City, Taiwan; Taichung, Taiwan; Taoyuan City, Taiwan
Newest research
PubMed records naming it or its code names, newest first.
- NBM-BMX, an HDAC8 Inhibitor, Overcomes Temozolomide Resistance in Glioblastoma Multiforme by Downregulating the β-Catenin/c-Myc/SOX2 Pathway and Upregulating p53-Mediated MGMT Inhibition.
Tsai CY, Ko HJ, Chiou SJ, et al. · Int J Mol Sci 2021
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.